Sugi Predict

Sugi Predict / Targets / PSMD8

PSMD8

26S proteasome non-ATPase regulatory subunit 8 · P48556 · PSMD8 on Sugi Atlas →

7,757 patent compounds predicted against PSMD8, 6,126 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL1478606 SCHEMBL1478606 0.58 12/20
SCHEMBL607010 SCHEMBL607010 0.56 12/20
SCHEMBL608381 SCHEMBL608381 0.53 12/20
SCHEMBL606616 SCHEMBL606616 0.51 12/20
SCHEMBL1477637 SCHEMBL1477637 0.57 11/20
SCHEMBL607972 SCHEMBL607972 0.55 11/20
SCHEMBL608782 SCHEMBL608782 0.54 11/20
SCHEMBL609278 SCHEMBL609278 0.54 11/20
SCHEMBL607553 SCHEMBL607553 0.54 11/20
SCHEMBL605822 SCHEMBL605822 0.54 11/20
SCHEMBL606932 SCHEMBL606932 0.53 11/20
SCHEMBL1477893 SCHEMBL1477893 0.53 11/20
SCHEMBL608362 SCHEMBL608362 0.53 11/20
SCHEMBL608599 SCHEMBL608599 0.53 11/20
SCHEMBL1327441 SCHEMBL1327441 0.53 11/20
SCHEMBL605129 SCHEMBL605129 0.52 11/20
SCHEMBL608009 SCHEMBL608009 0.52 11/20
SCHEMBL1478157 SCHEMBL1478157 0.52 11/20
SCHEMBL609081 SCHEMBL609081 0.52 11/20
SCHEMBL606926 SCHEMBL606926 0.52 11/20

Clinical trials — most relevant to PSMD8 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
A Prospective, Placebo Controlled, Double-Blind, Cross-over Study on the Effects of a Probiotic Preparation (VSL#3) on Metabolic Profile, Intestinal Permeability, Microbiota, Cytokines and Chemokines Expression and Other Inflammatory Markers in Pediatric Patients With Crohn's Disease PHASE4UNKNOWN
Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitors on Sarcopenia in Hemodialysis Patients PHASE4NOT_YET_RECRUITING
Doxorubicin and Bortezomib in Treating Patients With Liver Cancer PHASE2COMPLETED
Bortezomib in Treating Patients With Mantle Cell Lymphoma PHASE2COMPLETED
Tamoxifen and Bortezomib to Treat Recurrent Brain Tumors PHASE2COMPLETED
Desferal Administration to Improve the Impaired Reaction to Hypoxia in Diabetes PHASE2UNKNOWN
Biologic Correlative Taxotere/AC PHASE2COMPLETED
Colchicine for Amyotrophic Lateral Sclerosis PHASE2COMPLETED
MLN9708 and Dexamethasone for High-Risk Smoldering Multiple Myeloma PHASE2WITHDRAWN
Phase II Study of Vandetanib in Individuals With Kidney Cancer PHASE2COMPLETED
A Phase 2 Study to Investigate the Clinical Activity of IPI-504 in Patients With Hormone-resistant Prostate Cancer PHASE2COMPLETED
Targeting Endoplasmic Reticulum Stress in Human Hypertension PHASE1/PHASE2RECRUITING
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck PHASE1COMPLETED
PS-341 in Treating Patients With Advanced Solid Tumors or Lymphoma PHASE1COMPLETED
Study of Patients With Stage IV Malignant Melanoma Using PS-341 (Bortezomib, Velcade) and Interferon-alpha-2b in Malignant Melanoma PHASE1COMPLETED
GO-203-2C + Bortezomib For Relapsed Or Refractory MM PHASE1WITHDRAWN
The PREServation of MUScle Function in Critically Ill Patients (PRESMUS) nanUNKNOWN
Effect of Diaphragm Stimulation During Surgery nanCOMPLETED
Differential Gene Expression of Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis nanUNKNOWN
Clinical Study of 68Ga-DOTA-BLP PET Imaging in Noninvasive Diagnosis of Malignant Tumors nanNOT_YET_RECRUITING
Evaluation of Proteasome as a Marker of Hepatocellular Carcinoma in Cirrhotic Patients Following Curative Treatment nanUNKNOWN
Cardiovascular Complications of Carfilzomib Treatment nanUNKNOWN
Mitochondrial Activity and Myosteatosis in the Cachexia of Cancers of the Upper Aerodigestive Tract nanUNKNOWN
Establishment of Human Cellular Disease Models for Wilson Disease nanCOMPLETED
Effect of Dietary Nitrate on Immobilization-induced Changes in Skeletal Muscle in Young Healthy Men nanRECRUITING
Autophagy in Systemic Lupus Erythematosus nanUNKNOWN
Low Dose Melphalan and Bortezomib for AML and High-Risk MDS nanCOMPLETED
Maximizing Mechanisms of Muscle Hypertrophy to Combat Sarcopenia in Older Adults nanCOMPLETED
Inhibition of SENP1 for the Suppression of OS Growth and Metastasis nanUNKNOWN
Collection of Blood Samples for DNA in Motor Neuron Disease nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a PSMD8 binder may also engage these)

ProteinNameSimilarity
Q9CX56 — 0.998 Q9CX56 →
Q3SYT7 — 0.991 Q3SYT7 →
Q9XUP3 — 0.987 Q9XUP3 →
KAT8 Histone acetyltransferase KAT8 0.987 landscape →
KDM5B Lysine-specific demethylase 5B 0.986 landscape →
Q5RE15 — 0.986 Q5RE15 →
Q05AS3 — 0.986 Q05AS3 →
DHX29 ATP-dependent RNA helicase DHX29 0.986 landscape →
Q294E0 — 0.986 Q294E0 →
Q9U3V9 — 0.985 Q9U3V9 →
Q5XI06 — 0.985 Q5XI06 →
Q6DKK2 — 0.984 Q6DKK2 →
Q5ZK92 — 0.984 Q5ZK92 →
A1A5P5 — 0.984 A1A5P5 →
A9JR78 — 0.984 A9JR78 →
Q9FHY0 — 0.984 Q9FHY0 →
Q7Z3E5 — 0.984 Q7Z3E5 →
Q8BX57 — 0.984 Q8BX57 →
Q5F3R2 — 0.984 Q5F3R2 →
Q9VDQ7 — 0.984 Q9VDQ7 →
Q2HJE1 — 0.984 Q2HJE1 →
Q6PGC1 — 0.983 Q6PGC1 →
Q9D1P2 — 0.983 Q9D1P2 →
Q2KI89 — 0.983 Q2KI89 →
Q9W3E1 — 0.983 Q9W3E1 →
KDM1A Lysine-specific histone demethylase 1A 0.983 landscape →
KDM5D Lysine-specific demethylase 5D 0.983 landscape →
Q61K76 — 0.983 Q61K76 →
Q5XG71 — 0.983 Q5XG71 →
Q9STV0 — 0.983 Q9STV0 →